ArticleInternational journal of clinical oncology2026

Clinical value of prostate-specific antigen halving time as a predictor of response to first-line systemic treatment for synchronous metastatic castration-sensitive prostate cancer.

Takanari Kambe et al.PubMed ↗Publisher ↗

No numbers read from the abstract.